ClinicalTrials.gg
Not yet recruitingNCT06779474Updated Apr 17, 2025

Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) for Colorectal Liver Metastases (CRLM)

An observational study in Colorectal Liver Metastases, sponsored by Yanhong Deng. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-17.

Sponsored by Yanhong Deng · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 487 studies in Neoplasm Metastasis with a site in China — 224 open to participants now, 264 under way, 40 of them phase 3. Neoplasm Metastasis · China.

Planned enrollment
72nd of 83
30 · median 180
Started
2025
with 61 others
Observational
83 of 487
43 open now
Primary completion
2030-05
later than 255 of 263 live
Registered
353rd of 487
by date

Among the 487 studies in Neoplasm Metastasis with a site in China, this one is the 72nd largest by planned enrollment of the 83 observational ones that give a count, is one of 62 that started in 2025, is one of 83 observational ones, reaches primary completion later than 255 of the 263 other live ones, and was the 353rd registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

224 of the 487 studies in Neoplasm Metastasis with a site in China are open now. Recruiting first, the newest first:

219 more — sign in →

All 224 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 487 studies in Neoplasm Metastasis with a site in China, or all of them as a file.
02

Study summary

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a procedure used for patients with initially unresectable colorectal liver metastases (CRLM). However, the procedure has been reported to be associated with high morbidity and mortality. Laparoscopic ALPPS has recently been reported as a minimally invasive technique that reduces perioperative risks. This study aimed to assess the safety and feasibility of full laparoscopic ALPPS in patients with CRLM.

03

Conditions studied

  • Colorectal Liver Metastases

Browse trials for

Keywords

  • Colorectal liver metastases
  • Associating liver partition and portal vein ligation for staged hepatectomy
  • Laparoscopic surgery
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are hospitalized at the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects > 18 years \< 75 of age.
  2. performance status 0-1.
  3. confirmed colorectal adenocarcinoma.
  4. Imaging (CT or MRI) or pathological confirmation of liver .
  5. grade A liver function.
  6. FLR/sTLV (standardized total liver volume) \< 30% (patients without underlying liver diseases)or \< 40% (patients with liver diseases, such as hepatic steatosis, cirrhosis, or liver damage after chemotherapy).
  7. The indication of surgery is evaluated by a multidisciplinary team attended by hepatobiliary surgeons, oncologists, hepatologists and radiologists.

Exclusion criteria

Exclusion Criteria:

  1. Patients with unresectable extrahepatic disease (except potentially resectable lung metastases) or primary tumor.
  2. Patients with severe concomitant diseases who are intolerance of major liver surgery by the judgment of the surgeon.
  3. Diagnosis of other malignant tumors within the past 5 years.
  4. Intention to become pregnant during the course of the study.
  5. Inability to comply with the study protocol.
  6. Previous enrollment in the current study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Laparoscopic ALPPS group

    CRLM patients with insufficient future liver remnant who are performed laparoscopic associating liver partition with portal vein ligation for staged hepatectomy

    Procedure: Laparoscopic ALPPS

Interventions

  • ProcedureLaparoscopic ALPPS

    Laparoscopic Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Morbidity and mortality of laparoscopic ALPPS

    Time frame: within the first 90 days after the first stage of ALPPS

Secondary outcomes

  1. Resection rate

    R0 resection rate of laparoscopic ALPPS

    Time frame: within the first 14 days after the second stage of ALPPS

  2. Survival

    follow-up after the surgery every 3 months, to evaluate recurrence, death, analysis 1-year, 3-year overall survival rates,disease-free survival rates and recurrence rate.

    Time frame: 3 years

  3. Future liver remnant after surgery

    Future liver remnant volume calculated 3 months after the stage 2 surgery

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Study protocol

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for May 2030, 60 months later.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 60 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2025
First posted
Jan 16, 2025
StartEst.
May 1, 2025
Primary completionEst.
May 1, 2030
CompletionEst.
May 1, 2030
Last update
Apr 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06779474
Lead sponsor
Yanhong Deng
Responsible party
Yanhong Deng (Director, Clinical Professor, Sun Yat-sen University) — Sponsor-investigator
First posted
Jan 16, 2025
Start date
May 1, 2025 (estimated)
Primary completion
May 1, 2030 (estimated)
Completion
May 1, 2030 (estimated)
Last update
Apr 17, 2025

Study contacts

Weidong Pan
Contact
panwd@mail.sysu.edu.cn
86-13925032539
Zheyu Zheng
Contact
doctorfishzzy@126.com
86-13535003060

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion